Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab in pediatric moderate to severe Crohn's disease
NL-OMON31545Phase 3Active, not recruiting
- Sponsor
- Abbott Laboratories
- Start
- Oct 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, double-blind trial of adalimumab in Crohn's disease, sponsored by Abbott Laboratories. Primary endpoint: Primary efficacy endpoint. Started Oct 2008; status: active, not recruiting.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON31545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31545.